Prostate cancer starts in the prostate gland–and is the second most common form of cancer in men. Cancer spreads, or metastasised, from the prostate to other areas of the body with the help of the bloodstream or lymphatic system, which results in the metastasis of tumour, leading to the development of Advanced Prostate Cancer.
According to Global cancer statistics 2012, the incidence of prostate cancer in Japan is rapidly increasing, even though it is still much lower than in Western populations. Inoue et al. reported that in a population of 151 patients with CRPC, 84% had bone metastases at diagnosis.
As per the Cancer Research UK, among the diagnosed prostate cancer cases in England, Scotland, 17% and 34% of prostate cancer patients have metastases at diagnosis (stage IV). It is found to be more common in the adults aged (39%) than the younger persons (30%).
DelveInsight's "Castrate-Resistant Prostate Cancer (CRPC) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Castrate-Resistant Prostate Cancer (CRPC) Market, historical and forecasted epidemiology, the pipeline insight as well as the Castrate-Resistant Prostate Cancer (CRPC) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Castrate-Resistant Prostate Cancer (CRPC) market report also covers emerging drugs, current treatment practices, Castrate-Resistant Prostate Cancer (CRPC) market shares of the individual therapies, current and forecasted Castrate-Resistant Prostate Cancer (CRPC) Market Size segmented by seven major markets.
The report provides a detailed current Castrate-Resistant Prostate Cancer (CRPC) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Castrate-Resistant Prostate Cancer (CRPC) Market Growth
Castrate-Resistant Prostate Cancer (CRPC) Market Size is expected to increase owing to the increasing incidence as well as treatment of CRPC with the accessible novel therapies in the 7MM.
The Castrate-Resistant Prostate Cancer (CRPC) market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Castrate-Resistant Prostate Cancer (CRPC) market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Castrate-Resistant Prostate Cancer (CRPC) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Castrate-Resistant Prostate Cancer (CRPC) Epidemiology Forecast
The Castrate-Resistant Prostate Cancer (CRPC) epidemiology section covers insights about historical and current Castrate-Resistant Prostate Cancer (CRPC) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Castrate-Resistant Prostate Cancer (CRPC) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Castrate-Resistant Prostate Cancer (CRPC) Market Growth